Arrowhead Pharmaceuticals, Inc.

Ownership Transactions Reported by 16 Insiders

Symbol
ARWR on Nasdaq
Location
177 E Colorado Blvd, Suite 700, Pasadena, CA

Insiders trading volume in the past year

Arrowhead Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Christopher Anzalone Chief Executive Officer, Director $75.9M -$1.03M -1.34% Feb 7, 2025
Patrick O'Brien COO and General Counsel $10.4M -$736K -6.62% Jan 4, 2025
Kenneth Myszkowski Chief Financial Officer $8.97M -$2.3M -20.4% Jan 4, 2025
Javier San Chief Medical Officer $7.42M Jan 4, 2024
James Hamilton Chief Discovery/Trans Medicine $5.47M -$817K -13% Jan 4, 2025
James Hassard Chief Commercial Officer $3.95M Jun 22, 2021
Tracie Oliver Chief Commercial Officer $3.21M -$237K -6.88% Jul 2, 2024
Michael Perry Director $3.02M Dec 18, 2024
Douglas B. Given Director $2.74M -$122K -4.25% Dec 16, 2024
Mauro Ferrari Director $1.78M Dec 18, 2024
William D. Waddill Director $1.31M -$165K -11.1% Dec 18, 2024
Marianne De Backer Director $1.17M Jan 10, 2023
Hongbo Lu Director $1.08M +$145K +15.5% Dec 18, 2024
Victoria Vakiener Director $872K -$239K -21.5% Dec 18, 2024
Douglas S. Ingram Director $771K Feb 6, 2025
Adeoye Olukotun Director $751K -$77.1K -9.31% Jan 23, 2025

Recent Insider Transactions by Companies or Individuals for Arrowhead Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.